Overview
TC Biopharm (Holdings) Plc, based in the United Kingdom, operates within the biotechnology sector, focusing on pioneering immunotherapy treatments that leverage the immune system to combat diseases. The company is primarily engaged in the development of innovative cell therapies targeting a broad range of cancers and viral infections. A key project of TC Biopharm includes the advancement of its CAR-T products, which are designed to specifically target and destroy cancer cells while avoiding harm to normal cells. Their portfolio also showcases groundbreaking work in gamma delta T cells therapies, positioning the company at the forefront of cancer treatment research that could potentially revolutionize oncological and antiviral therapeutics.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The operating income for TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock) as of December 31, 2024 is -12.82 MM.
- The net income for TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock) as of December 31, 2024 is -12.15 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2024-12-31 | -12.82 | -12.15 | |
| 2024-09-30 | -12.34 | -11.86 | |
| 2024-06-30 | -11.86 | -11.57 | |
| 2024-03-31 | -13.50 | -8.59 | |
| 2023-12-31 | -14.24 | -5.91 | |
| 2023-09-30 | 1.43 | -13.16 | -3.69 |
| 2023-06-30 | 2.86 | -12.08 | -1.47 |
| 2023-03-31 | 3.35 | -12.31 | -2.20 |
| 2022-12-31 | 3.84 | -12.08 | -1.31 |
| 2022-09-30 | 2.91 | -12.33 | -4.30 |
| 2022-06-30 | 1.98 | -12.40 | -10.42 |
| 2022-03-31 | 1.98 | -9.84 | -12.00 |
| 2021-12-31 | 1.98 | -7.29 | -13.58 |
| 2021-09-30 | 1.98 | -6.57 | -11.00 |
| 2021-06-30 | 1.98 | -5.93 | -5.17 |
| 2021-03-31 | 1.98 | -6.41 | -5.31 |
| 2020-12-31 | 1.98 | -6.89 | -5.46 |
Income Statement: EPS
- The earnings per share basic for TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock) as of December 31, 2024 is -128.79.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2024-12-31 | -128.79 | |
| 2024-09-30 | -228.92 | -227.71 |
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock) as of December 31, 2024 is -12.57 MM.
- The cash from investing activities for TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock) as of December 31, 2024 is -0.09 MM.
- The cash from financing activities for TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock) as of December 31, 2024 is 11.46 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2024-12-31 | -12.57 | -0.09 | 11.46 |
| 2024-09-30 | -10.70 | -0.06 | 9.76 |
| 2024-06-30 | -8.84 | -0.03 | 8.06 |
| 2024-03-31 | -10.04 | -0.07 | 5.50 |
| 2023-12-31 | -10.54 | -0.21 | 8.52 |
| 2023-09-30 | -11.90 | -0.33 | 9.09 |
| 2023-06-30 | -13.25 | -0.45 | 9.66 |
| 2023-03-31 | -13.76 | -0.41 | 16.02 |
| 2022-12-31 | -15.29 | -0.31 | 18.65 |
| 2022-09-30 | -14.64 | -0.25 | 18.53 |
| 2022-06-30 | -12.53 | -0.16 | 18.15 |
| 2022-03-31 | -9.06 | -0.15 | 12.34 |
| 2021-12-31 | -5.58 | -0.14 | 6.53 |
| 2021-09-30 | -4.56 | -0.14 | 3.80 |
| 2021-06-30 | -4.14 | -0.16 | 4.75 |
| 2021-03-31 | -3.78 | -0.18 | 4.09 |
| 2020-12-31 | -3.43 | -0.20 | 3.43 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 |
Management Effectiveness
- The roa for TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock) as of December 31, 2024 is -1.36.
- The roe for TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock) as of December 31, 2024 is -4.53.
- The roic for TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock) as of December 31, 2024 is -2.70.
- The croic for TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock) as of December 31, 2024 is -0.28.
- The ocroic for TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock) as of December 31, 2024 is -2.79.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2024-12-31 | -1.36 | -4.53 | -2.70 | -0.28 | -2.79 |
| 2024-09-30 | -1.33 | -4.42 | -2.63 | -0.24 | -2.37 |
| 2024-06-30 | -0.78 | -25.94 | -3.06 | -1.68 | -3.58 |
| 2024-03-31 | -0.54 | -1.32 | -0.52 | -2.35 | |
| 2023-12-31 | -0.34 | -0.74 | -0.65 | -2.36 | |
| 2023-09-30 | -0.11 | -1.52 | -0.35 | -0.92 | -2.73 |
| 2023-06-30 | -0.11 | -1.52 | -0.35 | -0.92 | -2.73 |
| 2023-03-31 | -0.16 | -2.16 | -0.70 | 0.62 | -4.40 |
| 2022-12-31 | -0.61 | -1.57 | 1.39 | -5.15 | |
| 2022-09-30 | -0.61 | -1.57 | 1.39 | -5.15 | |
| 2022-06-30 | -1.54 | -2.35 | 1.29 | -2.83 | |
| 2022-03-31 | -1.78 | -2.71 | 0.74 | -2.04 | |
| 2021-12-31 | -1.87 | -179.94 | 10.85 | -73.97 | |
| 2021-09-30 | |||||
| 2021-06-30 | -0.51 | ||||
| 2021-03-31 | -0.52 | ||||
| 2020-12-31 | -0.54 |
Gross Margins
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | 1.00 | -6.02 | -9.46 |
| 2024-03-31 | 1.00 | -4.14 | -9.97 |
| 2023-12-31 | 1.00 | -2.58 | -9.14 |
| 2023-09-30 | 1.00 | -0.54 | -4.09 |
| 2023-06-30 | 1.00 | -0.54 | -4.09 |
| 2023-03-31 | 1.00 | -0.66 | -3.67 |
| 2022-12-31 | 1.00 | -1.49 | -4.21 |
| 2022-09-30 | 1.00 | -1.49 | -4.21 |
| 2022-06-30 | 1.00 | -5.26 | -6.27 |
| 2022-03-31 | 1.00 | -6.06 | -4.98 |
| 2021-12-31 | 1.00 | -6.86 | -3.68 |
| 2021-09-30 | 1.00 | -5.56 | -3.32 |
| 2021-06-30 | 1.00 | -2.61 | -3.00 |
| 2021-03-31 | 1.00 | -2.69 | -3.24 |
| 2020-12-31 | 1.00 | -2.76 | -3.48 |
Identifiers and Descriptors
| Central Index Key (CIK) | 1872812 |
